or
forgot password

    • cancer clinical trials in nyack, NY

    • Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
    Hematology Oncol. Associates Rockland
    Nyack, New York 10960
    Breast Cancer
    ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
    Union State Bank Cancer Center
    Nyack, New York 10960
    Prostate Cancer
    S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
    Union State Bank Cancer Center at Nyack Hospital
    Nyack, New York 10960-1998
    Breast Cancer
    Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
    Union State Bank Cancer Center at Nyack Hospital
    Nyack, New York 10960-1998
    Kidney Cancer
    S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
    Union State Bank Cancer Center at Nyack Hospital
    Nyack, New York 10960-1998
    Breast Cancer
    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
    Nyack Hospital
    Nyack, New York 10960
    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer
    Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery
    Nyack Hospital
    Nyack, New York 10960
    Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
    Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
    Nyack Hospital
    Nyack, New York 10960
    Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
    Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer
    Hematology Oncology Associates of Rockland
    Nyack, New York 10960
    Non-small Cell Lung Cancer
    Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
    1199.14.1151 Boehringer Ingelheim Investigational Site
    Nyack, New York
    Carcinoma, Non-Small-Cell Lung
    S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung Cancer
    Union State Bank Cancer Center at Nyack Hospital
    Nyack, New York 10960-1998
    Lung Cancer
    BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
    Hematology Oncology Associates of Rockland
    Nyack, New York 10960
    Renal Cell Carcinoma
    A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
    Nyack Hospital
    Nyack, New York 10960
    Prostate Cancer
    Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
    Nyack Hospital
    Nyack, New York 10960
    Prostatic Neoplasms
    Clinical Trial for Ovarian Cancer (OvaRex®)
    Nyack Hospital
    Nyack, New York 10960
    Ovarian Cancer
    Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
    Hematology-Oncology Associates of Rockland
    Nyack, New York 10956
    Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
    Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
    Cancer Center at Nyack Hospital
    Nyack, New York 10960
    Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
    TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
    Hematology-Oncology Associates of Rockland

    Trial Locations
    Hematology-Oncology Associates of Rockland
    The Union State Bank Cancer Center at Nyack Hospital
    Ovarian Neoplasms
    Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
    Hematology-Oncology Associates of Rockland
    Nyack, New York 10956
    Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
    Study of XL999 in Patients With Non-small Cell Lung Cancer
    Hematology-Oncology Associates of Rockland
    Nyack, New York 10956
    Non-small Cell Lung Cancer
    Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
    Hematology-Oncology Associates of Rockland
    Nyack, New York 10956
    Non-Small-Cell Lung Cancer
    AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
    Hematology Oncology Associates of Rockland
    Nyack, New York 10960
    Pancreatic Cancer
    Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
    Investigative Site
    Nyack, New York
    Kidney Cancer
    Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
    Hematology Oncology Associates of Rockland
    Nyack, New York 10960
    Breast Neoplasms
    ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
    Hematology Oncology Associates of Rockland
    Nyack, New York 10960
    Non-Small Cell Lung Cancer
    Maintenance Study on the Long Term Safety of XL999
    Hematology Oncology Associates of Rockland Union State Bank Cancer Center
    Nyack, New York 10960
    Advanced Malignancies
    A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
    Hematology- Oncology Associates of Rockland, PC
    Nyack, New York 10960
    Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
    A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
    Hematology Oncology Associates of Rockland
    Nyack, New York 10960
    Chemotherapy-Induced Nausea and Vomiting